Search Results
Your search for Colorectal matches 3163 pages
Showing 851 - 900Researchers Identify Significant Differences in Tumor Characteristics Between Younger and Older Patients With Cancer
Investigators at Weill Cornell Medicine have identified significant differences in the molecular characteristics of tumors from younger and older patients with cancer across several cancer types. Their research, published by Shah et al in Cell Reports, suggests that cancer treatment could...
Trends in Incidence of Colorectal Cancer Among Black and White Individuals Aged 40 to 49 Years From 2000 to 2017
In a study reported in JAMA Network Open, Montminy et al found that the incidence of colorectal adenocarcinoma in people aged 40 to 49 years in the United States has increased in White individuals and remained stable in Black individuals between 2000 and 2017, with incidence rates being equivalent...
Five Percent Overall Medicare Reimbursement Cut Estimated for Medical Oncology in 2022
On November 2, 2021, the Centers for Medicare & Medicaid Services (CMS) released the 2022 Medicare Physician Fee Schedule (PFS) and Quality Payment Program (QPP) final rule. Although ASCO will analyze the rule in greater detail in the coming days, initial highlights from the rule are outlined...
No Disease-Free Survival Difference With Longer Anastrozole Treatment After Endocrine Therapy in HR-Positive Breast Cancer
In an Austrian Breast and Colorectal Cancer Study Group phase III trial (ABCSG-16/SALSA) reported in The New England Journal of Medicine, Michael Gnant, MD, of the Comprehensive Cancer Center, Medical University of Vienna, and colleagues found no difference in disease-free survival with 2 vs 5...
Expert Point of View: Paul Wheatley-Price, MRCP
During an International Association for the Study of Lung Cancer (IASLC) press briefing, Paul Wheatley-Price, MRCP, commented as the patient advocate on the panel. Dr. Wheatley-Price is Associate Professor of Medicine at the University of Ottawa, lung cancer disease site lead at Ottawa Hospital...
In Case You Missed It: Brief Highlights From ESMO Congress 2021
The ASCO Post has published a wealth of practice-changing studies and news about other advances presented during the European Society for Medical Oncology (ESMO) Congress 2021. In addition to the biggest news from this international meeting, here are several summaries of interesting study findings...
Long-Term Outcomes With Chemoradiotherapy Before vs After Chemotherapy in the Total Neoadjuvant Treatment of Locally Advanced Rectal Cancer
Long-term results of a German phase II trial (CAO/ARO/AIO-12) reported in JAMA Oncology by Fokas et al showed similar disease outcomes, chronic toxicity, and quality of life with chemoradiotherapy before vs after chemotherapy in the total neoadjuvant treatment of patients with locally advanced...
Thomas Gruenberger, MD, Shares Thoughts on Radiotherapy for Colorectal Liver Metastases
Invited discussant of the phase III EPOCH trial, Thomas Gruenberger, MD, a surgical oncologist at the Clinic Favoriten, Health Network Vienna, noted that the trial’s “intention was fulfilled,” thus making it the “first positive phase III trial that prolonged both progression-free and hepatic...
For Liver Metastases, Transarterial Radioembolization With Yttrium-90 Plus Chemotherapy May Delay Disease Progression
In the international phase III EPOCH trial, patients with colorectal liver metastases who experienced disease progression on first-line therapy derived significant benefit from treatment with transarterial yttrium Y-90 radioembolization in combination with systemic chemotherapy, according to Mary...
Treatment Adherence, Toxicity, and Outcomes With Adjuvant Fluoropyrimidine Plus Oxaliplatin in Early-Onset Colorectal Cancer
In an analysis of data from the International Duration Evaluation of Adjuvant Chemotherapy (IDEA) database reported in the Journal of Clinical Oncology, Fontana et al found a greater risk of relapse and cancer-specific mortality after adjuvant fluoropyrimidine/oxaliplatin chemotherapy in patients...
U.S. Multisociety Task Force on Colorectal Cancer Releases Updated Screening Recommendations
The U.S. Multisociety Task Force on Colorectal Cancer—representing the American College of Gastroenterology, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy—has updated its colorectal cancer screening recommendations, which were last published...
Medication Nonadherence Among Cancer Survivors: Are Indirect Health-Care Costs to Blame?
Approximately 1 in 10 long-term survivors of cancer fails to take medications as prescribed due to financial hardship, according to research presented at the 2021 ASCO Quality Care Symposium.1 However, indirect health-care costs—not drug copays—may be responsible, the study investigators ...
Study Finds Lack of Health Insurance May Hinder Recommended Cancer Screening in Unemployed Adults
In a recent study published by Stacey Fedewa, PhD, and colleagues in the journal Cancer, unemployed individuals were less likely to have health insurance and be up to date on getting recommended cancer screening tests. Analyses revealed that their lack of health insurance coverage accounted for...
Expert Point of View: Michaela A. Dinan, PhD
The invited discussant of the study on out-of-pocket costs of cancer care, Michaela A. Dinan, PhD, Co-Leader of Cancer Prevention and Control at Yale Cancer Center and Associate Professor of Chronic Disease Epidemiology at the Yale School of Public Health, Connecticut, underscored the study’s key...
Out-of-Pocket Costs on the Rise for the Four Most Common Cancers, Study Finds
Rising cost-sharing requirements from private insurance have exacerbated the financial burden for patients with cancer, according to research presented at the 2021 ASCO Quality Care Symposium.1 Analysis of claims data on the four most prevalent cancers in the United States—female breast,...
Do Solid Organ Transplant Recipients With a Previous Cancer Diagnosis Have High Cure Probabilities?
In a study reported in the Journal of Clinical Oncology, Engels et al found that patients with a previous cancer diagnosis who underwent solid organ transplantation had high cancer cure probabilities. Additionally, posttransplantation cancer-specific survival was associated with cancer cure...
Study Evaluates Virtual vs In-Person Visits and Access to Lung Cancer Screening
Findings from a novel telemedicine effort to screen patients for lung cancer screening during the COVID-19 pandemic show that virtual single-visit screenings may be just as effective as single-visit screenings done in person, according to a study presented by Magarinos et al at the American College ...
Do Diet-Related Molecules Play a Role in the Development of Aggressive Prostate Cancer?
Cleveland Clinic researchers have shown that diet-associated molecules in the gut may be associated with aggressive prostate cancer, suggesting dietary interventions may help reduce risk. These findings were published by Reichard et al in Cancer Epidemiology, Biomarkers & Prevention. While...
First-Round Results of Prostate Cancer Screening for Men With Pathogenic Variants in Mismatch Repair Genes
As reported in The Lancet Oncology by Bancroft et al, the first round of prostate cancer screening in the IMPACT study of men with pathogenic variants in mismatch repair genes showed an increased risk of prostate cancer in carriers of MSH2 and MSH6 variants compared with noncarrier controls. As...
Study Finds Similar Survival Rates Among Patients With Metastatic Colorectal Cancer Younger and Older Than Age 50
Even though patients with metastatic colorectal cancer younger than age 50 tend to be more fit and receive more intensive treatment than older patients, survival for both groups is roughly the same, according to a study published by Lipsyc-Sharf et al in the Journal of the National Cancer...
Expert Point of View: Pierre Laurent-Puig, MD
The invited discussant of the FOCUS4-C trial was Pierre Laurent-Puig, MD, Professor of Medicine, Université de Paris, Institut du Cancer Paris CARPEM. According to Dr. Laurent-Puig, the “promising results” for the WEE1 inhibitor adavosertib in colorectal cancer in the FOCUS4-C trial could apply to ...
FOCUS4-C Trial: Hint of Activity Reported With Adavosertib in Metastatic Colorectal Cancer
The novel WEE1 inhibitor adavosertib, given after induction chemotherapy, yielded a 65% reduction in the risk of disease progression or death compared with active monitoring in patients with metastatic colorectal cancer and TP53/RAS mutations, according to the randomized phase II FOCUS4-C trial....
Annual Report to the Nation, Part 2: Focus on Patient Economic Burden Associated With Cancer Care
Part 2 of the latest Annual Report to the Nation on the Status of Cancer—provided by the American Cancer Society, National Cancer Institute, Centers for Disease Control and Prevention, and North American Association of Central Cancer Registries—has found that patients with cancer in the United...
Expert Point of View: Federica Di Nicolantonio, MD, PhD
“KRAS G12C inhibitors as monotherapy yield a relatively low overall response rate, but when you combine them with an EGFR [epidermal growth factor receptor] inhibitor, the response rate is nearly double,” said Federica Di Nicolantonio, MD, PhD, Professor of Oncology at the University of Turin in...
KRAS G12C Inhibitor Adagrasib Shows Activity in Colorectal Cancer
Adagrasib, a covalent inhibitor of KRAS G12C, combined with cetuximab, showed activity in patients with metastatic colorectal cancer in the phase I/II KRYSTAL-1 trial, as presented during a Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2021 by Jared Weiss, MD,...
FDA Expands Cetuximab Label for Encorafenib Combination in BRAF V600E Mutation–Positive Metastatic Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has granted approval of a new indication for the EGFR inhibitor cetuximab (Erbitux) in combination with encorafenib (Braftovi) for the treatment of adults with metastatic colorectal cancer and a BRAF V600E mutation, as detected by an FDA-approved test,...
Cleveland Clinic Launches Center for Young-Onset Colorectal Cancer
According to the National Cancer Institute, cases of colorectal cancer in patients younger than age 50 have grown by more than 50% since the 1990s. Cleveland Clinic has addressed this trend with the establishment of a center focused on the diagnosis, care, and research of young-onset colorectal...
Financial Toxicity Associated With Atherosclerotic Cardiovascular Disease, Cancer, and Both in U.S. Adult Patients
In a study of National Health Interview Survey (NHIS) data reported in JACC: CardioOncology, Javier Valero-Elizondo, MD, MPH, of Houston Methodist DeBakey Heart and Vascular Center, and colleagues, found that U.S. adult patients aged 18 to < 65 years with atherosclerotic cardiovascular disease...
MSK Announces Appointment of Deb Schrag, MD, FASCO, MPH, as Chair of the Department of Medicine
Deb Schrag, MD, FASCO, MPH, has been named the new Chair of the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSK). Dr. Schrag has a deep familiarity with MSK, having previously spent 8 years at the institution as a physician and faculty member. She joins MSK from the...
Did Change in PSA-Based Screening Recommendation Hinder Prostate Cancer–Specific Survival?
Prostate-specific antigen (PSA) screening recommendations made by the U.S. Preventive Services Task Force (USPSTF) in 2012 may have led to worse outcomes for insured patients with prostate cancer, according to data presented at the 2021 ASCO Quality Care Symposium.1 Findings from the retrospective...
Nivolumab/Low-Dose Ipilimumab Produces Responses in Patients With MSI-H/dMMR Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Heinz-Josef Lenz, MD, and colleagues, in the phase II CheckMate 142 trial, first-line treatment with nivolumab plus low-dose ipilimumab produced a high rate of durable responses in a cohort of patients who had received no prior treatment for...
Filippo Pietrantonio, MD, and Federica Morano, MD, on Colorectal Cancer and the MAYA Trial Strategy: Temozolomide, Ipilimumab, and Nivolumab
Filippo Pietrantonio, MD, and Federica Morano, MD, both of the Istituto Nazionale dei Tumori, discuss results from the MAYA trial, which provided proof of concept that temozolomide-induced hypermutation may be exploited to achieve durable responses to low-dose ipilimumab plus nivolumab in patients...
Primary Tumor Resection Followed by Systemic Treatment vs Systemic Treatment Alone in Metastatic Colorectal Cancer: 60-Day Mortality
As reported in JAMA Surgery by van der Kruijssen et al, 60-day post–random assignment mortality results in the Danish/Dutch phase III CAIRO4 trial showed higher rates of mortality in patients with metastatic colorectal cancer who received primary tumor resection plus systemic treatment vs those...
Study Examines Cost of Cancer Care in the United States in 2018
Care for the 15 most prevalent types of cancer in the United States cost approximately $156.2 billion for about 402,000 privately insured adult patients in 2018, according to a report published by Nicholas G. Zaorsky, MD, and colleagues in JAMA Network Open. The research team also found that...
Rates of Diagnosis of Gastrointestinal Cancers—and Stage at Diagnosis—Before and During the COVID-19 Pandemic in Japan
In a study reported in JAMA Network Open, Kuzuu et al found that the COVID-19 pandemic in Japan was associated with reduced rates of new diagnoses, as well as reduced rates of diagnosis at earlier stages, for some gastrointestinal cancers. Study Details The retrospective cohort study included data...
Second Primary Cancers in Patients With Neuroendocrine Tumors
In a population-based study reported in a research letter in JAMA Oncology, Bateni et al found that 8% of patients with neuroendocrine tumors (NETs) developed second primary cancers over approximately 7.5 years of follow-up, with types of secondary malignancies differing according to NET type. The...
Does a Longer Interval Before Surgery Among Patients With Locally Advanced Rectal Cancer Lead to Worse Survival?
In an Italian retrospective cohort study reported in JAMA Surgery, Deidda et al found that a longer vs shorter delay to surgery among patients with locally advanced rectal cancer with minor or no pathologic response to neoadjuvant chemoradiotherapy was associated with significantly poorer overall...
Jenny F. Seligmann, MBChB, PhD, on Colorectal Cancer: Adavosertib Compared With Active Monitoring
Jenny F. Seligmann, MBChB, PhD, of the University of Leeds, discusses phase II findings that suggest adavosertib improved progression-free survival, compared with active monitoring, by inhibiting the WEE1 kinase in patients with RAS- and TP53-mutant metastatic colorectal cancer. In the trial,...
Two Studies Show Health-Care Costs May Impact Follow-up Care After Cancer Screening
Eleven years ago this month, the scans and exams that hold the most power to spot the early signs of cancer became available for free to many American adults through the passing of the Affordable Care Act. Now, two new studies show that when those screening tests reveal potentially troubling signs, ...
Radioembolization Plus Second-Line Chemotherapy for Colorectal Liver Metastases
In the phase III EPOCH trial reported in the Journal of Clinical Oncology, Mary F. Mulcahy, MD, and colleagues found that the addition of transarterial yttrium-90 radioembolization (TARE) to second-line chemotherapy significantly prolonged progression-free survival and hepatic progression–free...
Addition of Panitumumab to Fluorouracil/Leucovorin as Maintenance Therapy for RAS Wild-Type Metastatic Colorectal Cancer
In the German phase II PANAMA trial reported in the Journal of Clinical Oncology, Modest et al found that the addition of the monoclonal antibody panitumumab to fluorouracil (5-FU)/leucovorin maintenance therapy improved progression-free survival in patients with RAS wild-type metastatic colorectal ...
Adavosertib for Patients With TP53- and RAS-Mutant Metastatic Colorectal Cancer
As reported in the Journal of Clinical Oncology by Seligmann et al, the phase II FOCUS4-C trial has shown activity of the WEE1 kinase inhibitor adavosertib in patients with TP53- and RAS-mutant metastatic colorectal cancer with disease control after first-line chemotherapy. As state by the...
FDA Expands Cetuximab Label With Combination of Encorafenib for Pretreated BRAF V600E Mutation–Positive Metastatic Colorectal Cancer
The U.S. Food and Drug Administration (FDA) has granted approval of a new indication for cetuximab (Erbitux) in combination with encorafenib (Braftovi) for the treatment of adult patients with metastatic colorectal cancer and a BRAF V600E mutation, as detected by an FDA-approved test, after prior...
Hepatectomy With or Without Adjuvant mFOLFOX6 for Liver-Only Metastatic Colorectal Cancer: Disease-Free and Overall Survival
In the Japanese phase II/III JCOG0603 trial reported in the Journal of Clinical Oncology, Kanemitsu et al found that the addition of adjuvant mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) to hepatectomy improved disease-free survival in patients with liver-only metastatic colorectal cancer;...
Are Rates of Hepatocellular Carcinoma Rising in Rural Areas of the United States?
Historically, rates of hepatocellular carcinoma (HCC) have been lower in rural areas than urban regions. However, a recent study published by Zhou et al in Clinical Gastroenterology and Hepatology shows that while cases of HCC have begun slowing in urban communities in the United States, the...
Capecitabine Maintenance After First-Line Therapy for Metastatic Colorectal Cancer
In the FOCUS4-N trial reported in the Journal of Clinical Oncology, Adams et al found that capecitabine maintenance improved progression-free—but not overall—survival vs active monitoring in patients with stable disease or objective response after first-line therapy for metastatic colorectal...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Brunei Darussalam
With a population under half a million people, Brunei Darussalam is a small equatorial nation in Southeast Asia. Bordered by the South China Sea on the north, Brunei Darussalam is surrounded on all other sides by Malaysia, which separates the nation into two noncontiguous parts. Nearly two-thirds...
Building a ‘Better Normal’ of Oncology Care to Strengthen Global Health Security After the COVID-19 Pandemic
During the opening session of the 2021 ASCO Annual Meeting, Julio Frenk, MD, PhD, MPH, President of the University of Miami, gave a riveting presentation in which he described the devastating effects of the global COVID-19 pandemic on patients with cancer as well as on fragile and fragmented...
Overcoming the Disparities in Cancer Survival Among AYA Minority Patients
Although the National Cancer Institute (NCI) has identified adolescents and young adults (AYAs) with cancer as a distinct patient population from children and older adults with the disease, research into the diagnosis, treatment, and survivorship specific to this patient population has not kept...
Expert Point of View: Elena Élez, MD, PhD
Invited discussant of the two studies, Elena Élez, MD, PhD, of the Colon Cancer Program, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discussed the challenge of treating BRAF-mutant colorectal cancer and what the new data bring to that effort. Dr. Élez noted: “BRAF V600E–mutant metastatic ...
